scholarly journals Use of a Digital Medication Management System for Effective Assessment and Enhancement of Patient Adherence to Therapy (ReX): Feasibility Study

10.2196/10128 ◽  
2018 ◽  
Vol 5 (4) ◽  
pp. e10128 ◽  
Author(s):  
Ronit Shtrichman ◽  
Stefan Conrad ◽  
Kai Schimo ◽  
Ran Shachar ◽  
Ehud Machluf ◽  
...  
Keyword(s):  
Feasibility Study ◽  
Management System ◽  
Patient Adherence ◽  
Medication Management ◽  
Effective Assessment ◽  
Adherence To Therapy

scholarly journals Use of a Digital Medication Management System for Effective Assessment and Enhancement of Patient Adherence to Therapy (ReX): Feasibility Study (Preprint)

2018 ◽  
Author(s):  
Ronit Shtrichman ◽  
Stefan Conrad ◽  
Kai Schimo ◽  
Ran Shachar ◽  
Ehud Machluf ◽  
...  
Keyword(s):  
Real Time ◽  
Feasibility Study ◽  
Dose Regimen ◽  
Human Factor ◽  
Patient Adherence ◽  
Medication Management ◽  
Standard Of Care ◽  
Adherence Rate ◽  
Control Test ◽  
Adherence Data

BACKGROUND Medication nonadherence is a major problem in health care, imposing poor clinical outcomes and a heavy financial burden on all stakeholders. Current methods of medication adherence assessment are severely limited: they are applied only periodically, do not relate to actual pill intake, and suffer from patient bias due to errors, misunderstanding, or intentional nonadherence. ReX is an innovative medication management system designed to address poor patient adherence and enhance patient engagement with their therapy. ReX controls and tracks pills from the point of packaging right through to the patient’s mouth. ReX generates robust, real-time adherence data. The system enables patients to report outcomes, complete surveys, and receive messages and instructions. ReX includes a reusable drug dispensing unit, disposable cassette containing pills, and a cloud-based data portal. OBJECTIVE We aimed to evaluate ReX feasibility by human factor studies including evaluation of ReX safety; ReX acceptance and usability; and ReX efficacy of providing pills according to a preprogrammed dose regimen, managing reminders and adherence data, and enhancing the adherence rate compared with the standard of care. METHODS The ReX system was evaluated in 2 human factor, nonclinical feasibility studies. Human subjects used ReX for the administration of pill-shaped Tic Tac sweets. The initial study evaluated ReX use and pill intake administration; second was a self-controlled, 4-day home-use study. All subjects took pills at home, according to a preprogrammed dose regimen, for 4 days each via the device (ReX test) or from standard packaging (control test). The adherence rate (percent of pills taken) was measured by the study subject’s report, remaining pills count, and ReX records (in the ReX test). ReX safety and usability were evaluated by a questionnaire filled out by the subject. RESULTS The initial feasibility study evaluated usability and acceptance of the ReX novel approach to pill dispensing. All subjects successfully managed 2 pill intakes. The ReX device was rated as easy to use by 81% (48/59) of subjects. The 4-day home-use study evaluated the safety, efficacy, and usability of the ReX system. No adverse event occurred; no pill overdose or pill malformation was reported. The overall adherence rate in the ReX test was 97.6% compared with 76.3% in the control test (P<.001). Real-time, personalized reminders provided in the event of a delay in pill intake contributed to 18.0% of doses taken during the ReX test. The ReX system was found easy to use by 87% (35/40) of subjects; 90% (36/40) felt comfortable using it for their medication. CONCLUSIONS ReX’s novel “tracking to the mouth” technology was found usable and accepted by subjects. The assessment of adherence rates was reliable; adherence of subjects to the dose regimen was significantly enhanced when using ReX compared with the standard of care.

Effects of an electronic medication management system on pharmacists’ work in a paediatric hospital

2019 ◽  
Vol 49 (4) ◽  
pp. 317-323
Author(s):  
Melissa T. Baysari ◽  
Rae‐Anne Hardie ◽  
Peter Barclay ◽  
Johanna I. Westbrook
Keyword(s):  
Management System ◽  
Medication Management ◽  
Paediatric Hospital

Medication Management System Design for Isolated Patient Care

2020 ◽  
Author(s):  
Samhith Kethireddy Abigail Swamidoss ◽  
Bushra Alghamdi ◽  
Ronald L. Hickman ◽  
Shanina Knighton ◽  
Miriam Pekarek ◽  
...  
Keyword(s):  
System Design ◽  
Language Processing ◽  
Management System ◽  
Classification Tree ◽  
Medication Management ◽  
Care Providers ◽  
Medication Regimen ◽  
Dynamic Framework ◽  
Medication Schedule ◽  
Number Of Patients

Abstract Independent living care for polypharmacy patients can be complicated in those situations with medications that are pro re nata (PRN, “as needed”). Such medication regimen may involve multiple dosing whereby specific drug contraindications might be easily overlooked by hospice and palliative care patients, or by those isolated and not in regular contact with care providers. The goal of this paper is to describe the development steps and current design of a system providing medication decision support for isolated patients. With an increased number of patients living alone or isolated - a situation exacerbated during the COVID19 pandemic – polypharmacy patients may be challenged when PRN (as needed) medications confound what might ordinarily be a routine medication schedule. Central to our medication management system design is the so-called “conversational agent” that when integrated with a natural language processing front- end and classification tree algorithm provide a dynamic framework for patient self-management of medications. Research on “patient need” revealed patients were more likely to embrace the system if the system were autonomous, secure, and not cloud-based.

Measuring and Describing Dose Omissions using an Electronic Medication Management System

2012 ◽  
Vol 42 (4) ◽  
pp. 264-267 ◽  
Author(s):  
Eyra E Munzner ◽  
Susan A Welch ◽  
Katrina L Richardson
Keyword(s):  
Management System ◽  
Medication Management

scholarly journals Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease

2012 ◽  
Vol 5 ◽  
pp. CGast.S7613 ◽  
Author(s):  
Wojciech Blonski ◽  
Anna M. Buchner ◽  
Gary R. Lichtenstein
Keyword(s):  
Tumor Necrosis ◽  
Maintenance Treatment ◽  
Patient Adherence ◽  
Certolizumab Pegol ◽  
Controlled Trials ◽  
Double Blind ◽  
Double Blind Placebo ◽  
The Us ◽  
Necrosis Factor ◽  
Adherence To Therapy

Treatment with Anti-Tumor Necrosis Factor (anti-TNF) therapy has become a mainstay of therapy for patients with CD who are unresponsive to conventional medical management. Currently there are three anti-TNFα antibodies that have been approved by the US Food and Drug Administration for the treatment of CD, namely infliximab, adalimumab and certolizumab pegol (CZP). Several double blind placebo controlled trials determined that CZP is effective as induction and maintenance treatment in adult patients with CD regardless of their prior exposure to other anti-TNFα antibodies. This review discusses the efficacy of CZP and adherence to therapy with anti-TNFα antibodies in patients with CD.

A medication management system

1987 ◽  
Vol 21 (1) ◽  
pp. 73-91
Author(s):  
Nikitas Assimakopoulos
Keyword(s):  
Management System ◽  
Medication Management
Sign in / Sign up

Export Citation Format

Share Document